To: pete meyer who wrote (53 ) 4/14/1998 10:17:00 PM From: burner Read Replies (1) | Respond to
Immune Network Research Ltd - stockgroup.com . A series of five injections are scheduled through the end of April. The research team is monitoring changes to the immune system response by taking blood samples and biopsies. A positive effect on disease progression is anticipated based on the beneficial immune system responses noted in the first macaque study. In that study, mAb 1F7 injection increased the breadth and potency of virus neutralizing antibodies in all three monkeys chronically infected with SHIV-IIIB. No such changes occurred in a SHIV-IIIB-infected monkey with an isotype control antibody. The SHIV injected macaques will be monitored for several months to test whether macaques which have already developed retrovirus-induced immunodeficiency may benefit from mAb 1F7 in respect of lower viral load, lymphocyte subset normalization, or longer disease free survival. These findings would confirm that administration of mAb 1F7 promotes restoration of an already impaired immune system in a recognized primate model for HIV disease. The Principal Investigator for this study, Dr. Sybille Mller, has indicated that this research on the therapeutic effects of mAb 1F7 on viral load, CD4 and T-cell count in these SHIV 89.6P infected macaques is a critical step towards applying for human clinical trials. The study is under the direction of Drs. Sybille Mller and Heinz K”hler, of Immpheron, Inc. in collaboration with scientists at the Oregon Regional Primate Research Center, located in Beaverton, Oregon. stockgroup.com
